Immix Biopharma (IMMX) Payables (2020 - 2026)
Immix Biopharma (IMMX) posted Payables of $4.7 million for Q1 2026, down 52.56% sequentially from $10.0 million in Q4 2025, and down 48.81% YoY from $9.2 million in Q1 2025.
Immix Biopharma (IMMX) Payables (2020 - 2026) Analysis & Trends
Immix Biopharma has reported Payables for 7 years, with the latest figure at $4.7 million in Q1 2026.
- Quarterly Payables fell 48.81% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (down 48.81% YoY) and the FY2025 annual result came in at $10.0 million, up 85.05% from the prior year.
- Payables retreated to $4.7 million in Q1 2026 per IMMX's latest filing, from $10.0 million in the prior quarter.
- Over five years, Payables peaked at $10.7 million in Q3 2025 and troughed at $143074.0 in Q4 2022.
- A 5-year average of $4.4 million and a median of $3.5 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2023 and 2026: Payables jumped 901.59% in 2023, then sank 48.81% in 2026.
- Over 5 years, Payables stood at $143074.0 in 2022, then surged by 901.59% to $1.4 million in 2023, then jumped by 276.02% to $5.4 million in 2024, then surged by 85.05% to $10.0 million in 2025, then plunged by 52.56% to $4.7 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $4.7 million, $10.0 million, and $10.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 9.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.19 Mn |
| Mar 31, 2026 | 4.73 Mn |
| Dec 31, 2025 | 9.97 Mn |
| Sep 30, 2025 | 10.71 Mn |
| Jun 30, 2025 | 9.94 Mn |
| Mar 31, 2025 | 9.24 Mn |
| Dec 31, 2024 | 5.39 Mn |
| Sep 30, 2024 | 6.50 Mn |
| Jun 30, 2024 | 3.85 Mn |
| Mar 31, 2024 | 3.51 Mn |
| Dec 31, 2023 | 1.43 Mn |
| Sep 30, 2023 | 2.83 Mn |
| Jun 30, 2023 | 2.40 Mn |
| Mar 31, 2023 | 1.47 Mn |
| Dec 31, 2022 | 143,074.00 |
| Sep 30, 2022 | 646,457.00 |
| Jun 30, 2022 | 977,209.00 |
| Mar 31, 2022 | 355,679.00 |
| Dec 31, 2021 | 192,940.00 |
| Dec 31, 2020 | 302,344.00 |